Loading...
XSHE300146
Market cap2.69bUSD
Jan 17, Last price  
11.62CNY
1D
-0.17%
1Q
-10.87%
Jan 2017
-3.18%
IPO
92.80%
Name

Byhealth Co Ltd

Chart & Performance

D1W1MN
XSHE:300146 chart
P/E
11.34
P/S
2.10
EPS
1.02
Div Yield, %
1.55%
Shrs. gr., 5y
3.14%
Rev. gr., 5y
16.67%
Revenues
9.41b
+19.66%
66,850,336141,857,490205,290,366346,080,768657,963,6821,066,692,0931,482,241,9031,704,980,5362,266,043,0132,309,112,3663,110,795,3874,350,775,6275,261,799,4396,094,900,9437,431,278,1297,861,411,7529,406,813,736
Net income
1.75b
+26.01%
12,126,45926,705,00552,172,37192,105,877186,435,124280,354,339421,686,349502,594,966635,496,096535,211,834766,255,5621,002,184,99901,524,251,2451,753,979,2731,385,850,7181,746,309,643
CFO
2.05b
+48.77%
12,803,07025,364,46041,880,27454,606,252173,992,325111,224,133626,512,474560,640,271634,893,057684,648,483954,308,9971,349,053,2241,536,520,1031,566,364,3731,818,978,0271,378,929,7412,051,410,047
Dividend
Apr 22, 20240.9 CNY/sh
Earnings
Apr 24, 2025

Profile

By-health Co., Ltd. produces and sells dietary supplements worldwide. The company offers proteins and vitamins/minerals; and various products for skeleton and joints, heart and cerebral vessels, beauty maintenance, immunity boosting, weight management, vigor enhancement, eye nutrition, sleep improvement, blood glucose management, memory improvement, reproductive health, childhood nutrition, and pregnant women nutrition, as well as for liver, intestines, and stomach. It provides its products for children, men, women, and elderly people under the By-health and GymMax brand names through distributors, retail terminals, and online channels. The company was formerly known as Guangdong By-Health Biotechnology Co., Ltd. and changed its name to By-health Co., Ltd. in April 2012. By-health Co., Ltd. was founded in 1995 and is headquartered in Guangzhou, China.
URL
http://www.by-health.com/
IPO date
Dec 15, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,406,814
19.66%
7,861,412
5.79%
Cost of revenue
6,444,183
5,890,024
Unusual Expense (Income)
NOPBT
2,962,630
1,971,387
NOPBT Margin
31.49%
25.08%
Operating Taxes
417,179
293,525
Tax Rate
14.08%
14.89%
NOPAT
2,545,452
1,677,862
Net income
1,746,310
26.01%
1,385,851
-20.99%
Dividends
(306,084)
(1,190,216)
Dividend yield
1.06%
3.07%
Proceeds from repurchase of equity
(17,997)
BB yield
0.06%
Debt
Debt current
20,337
Long-term debt
322,922
7,831
Deferred revenue
84,812
Other long-term liabilities
77,652
671
Net debt
(5,500,084)
(4,762,837)
Cash flow
Cash from operating activities
2,051,410
1,378,930
CAPEX
(1,257,331)
Cash from investing activities
(1,417,626)
Cash from financing activities
(372,203)
FCF
1,715,751
3,353,325
Balance
Cash
6,438,128
4,791,006
Long term investments
(615,121)
Excess cash
5,352,666
4,397,935
Stockholders' equity
5,341,392
4,656,603
Invested Capital
7,140,116
6,388,375
ROIC
37.63%
25.26%
ROCE
23.45%
17.96%
EV
Common stock shares outstanding
1,695,446
1,700,363
Price
17.03
-25.37%
22.82
-15.36%
Market cap
28,873,450
-25.59%
38,802,278
-15.35%
EV
23,448,770
34,102,403
EBITDA
3,210,222
2,215,175
EV/EBITDA
7.30
15.39
Interest
4,711
2,203
Interest/NOPBT
0.16%
0.11%